Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults With Antiacetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension

Category Primary study
JournalNeurology
Year 2024
This article has no abstract
Epistemonikos ID: 2c22e9ac2b99bf7358bfd12d3fcc03bcd59f1286
First added on: Feb 07, 2025